Together, these results showed that adipocyte-secreted CCL2 contributed to cisplatin resistance through both paracrine signaling to tumor cells and autocrine stimulation of lipolysis in adipocytes, with both pathways being effectively targeted by CCR2 blockade. The gene discussed is CCL2; the disease is neoplasm.